Reaction
Osmotic Demyelination Syndrome reporting signals
As of the last recalculation, Osmotic Demyelination Syndrome appears in 730 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is TOLVAPTAN (PRR 80.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tolvaptan | 39 | 80.8 | 81.0 |
| Sodium Chloride Tablet | 93 | 41.1 | 41.2 |
| Sodium Chloride Tablets | 93 | 41.1 | 41.2 |
| Indapamide | 25 | 41.1 | 41.2 |
| Sodium Chloride | 97 | 40.2 | 40.3 |
| Basiliximab | 16 | 39.6 | 39.7 |
| Tacrolimus Ointment 0.1% | 126 | 34.7 | 34.7 |
| Tacrolimus Extended-Release Capsules | 126 | 34.6 | 34.6 |
| Tacrolimus | 142 | 31.9 | 31.9 |
| Thiamine Hydrochloride | 12 | 27.9 | 28.0 |
| Mycophenilic Acid | 19 | 26.8 | 26.8 |
| Ganciclovir | 8 | 22.5 | 22.5 |
| Ganciclovir Sodium | 8 | 21.8 | 21.8 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 21.4 | 21.4 |
| Lithium | 17 | 19.7 | 19.7 |
| Lithium Bromatum | 17 | 19.7 | 19.7 |
| Thiotepa | 5 | 15.0 | 15.0 |